Fatty acids are organic acids with at least one carboxyl (-C(=O)OH, -COOH or -CO2H) group and a long carbon chain that can be joined by double bonds, as in unsaturated fatty acids, or single bonds ...

“The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide ...

"The fourth quarter of 2024 was marked by two key announcements: the filing of patents covering, in particular, BioChaperone CagriSema—a stable combination of cagrilintide and semaglutide enabled by ...

compared to 82.5% for cagrilintide and 70.2% for semaglutide, the comparator drugs. Following the announcement, Novo Nordisk's stock price plunged nearly 18%, according to the lawsuit. The ...

“CagriSema is an investigational fixed-dose combination of a long-acting amylin analogue, cagrilintide 2.4 mg, and semaglutide 2.4 mg. Novo Nordisk is investigating the two molecules to determine if ...

Novo Nordisk will outlay $6.5bn in 2025 to ramp up production in the US. Image credit: Shutterstock / KK Stock. Compounders are on alert after the US Food and Drug Administration (FDA) declared the ...

Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement announced in its 2024 earnings report. The company has yet to secure a ...

Zealand Pharma is based in Denmark. Credit: Zealand Pharma via LinkedIn. Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing, with no agreement ...

This "flexibility" resulted in fewer than 60% of patients apparently completing the dose escalation period and thus being treated with "2.4 mg cagrilintide and 2.4 mg semaglutide once-weekly," the ...